Association for Molecular Pathology v. Myriad Genetics, Inc.

Holding: A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but synthetic complementary DNA (“cDNA”) is patent eligible because it is not naturally occurring.

 

JudgmentAffirmed in part and reversed in part., 9-0, in an opinion by Justice Thomas on June 13, 2013. Justice Scalia filed an opinion concurring in part and concurring in the judgment.

CLICK HERE FOR FULL VERSION OF THIS STORY